The expression of CD33 on various hematopoietic precursor cells, such as myeloid progenitor cells, monocytes, macrophages, granulocytes, and dendritic cells (DCs), raises concerns regarding the potential for on-target off-tumor effects90. Here, CD33 is linked to neoplasm.